

MAR 30 2011

Endoscopy
Smith & Nephew, Inc.
150 Minuteman Road
Andover, MA 01810
USA

T 978-749-1000
F 978-749-1443
www.smith-nephew.com

 We are **smith&nephew**

SECTION IV

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION

as required by the Safe Medical Devices Act of 1990 and codified in 21 CFR 807.92
upon which the substantial equivalence is based.

TRUCLEAR Morcellation System

Date Prepared: January 4, 2011

A. Submitter's Name:

Smith & Nephew, Inc., Endoscopy Division
150 Minuteman Road
Andover, MA 01810

B. Company Contact

Janice Haselton
Sr. Regulatory Affairs Specialist
T: 978-749-1494
F: 978-749-1443
E-mail: Janice.haselton@smith-nephew.com

C. Device Name

Trade Name: TRUCLEAR Morcellator System
Common Name: Mechanical Tissue Resection System
Classification Name: Hysteroscopes and Accessories

D. Predicate Devices

The Smith & Nephew TRUCLEAR Morcellator System is substantially equivalent in Intended Use and Fundamental Scientific Technology to the following legally marketed device in commercial distribution: Smith & Nephew IUR Morcellation System.

E. Description of Device

The TRUCLEAR Morcellator System was first introduced in K031787. The method of operation is mechanical resection and suction to cut and remove submucous myomas and endometrial polyps from the uterine lining. The system consists of a control unit, handpiece and footswitch. The system is used in conjunction with disposable hysteroscopic blades.

F. Intended Use

The TRUCLEAR Morcellator System is intended for use in gynecological procedures by trained professional gynecologists to resect and remove endometrial tissue for the following indications, submucous myomas and endometrial polyps.

G. Comparison of Technological Characteristics

The TRUCLEAR Morcellator System has the same fundamental technological characteristics as the unmodified predicate device and is substantially equivalent in design, materials and intended use as the unmodified predicate device. The proposed TRUCLEAR Morcellator System has the following similarities as the predicate device cleared in K031787:

- The same indications for use
- Utilizes the same operating principle
- Incorporates the same basic design
- Manufactured under the same Quality System

There are no significant differences between the proposed and predicate devices that raise new questions of safety or efficacy.

H. Summary Performance Data

The TRUCLEAR Morcellator System performance testing has demonstrated that the proposed device is substantially equivalent to the predicate device and the proposed modifications to increase the blade speed range does not raise new questions of safety and efficacy.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
10903 New Hampshire Avenue
Document Mail Center - WO66-G609
Silver Spring, MD 20993-0002

Ms. Janice Haselton
Senior Regulatory Affairs Specialist
Smith & Nephew, Inc.
150 Minuteman Road
ANDOVER MA 01810

Re: K110038

MAR 30 2011

Trade Name: TRUCLEAR Morcellation System
Regulation Number: 21 CFR §884.1690
Regulation Name: Hysteroscope and accessories
Regulatory Class: II
Product Code: HIH
Dated: March 1, 2011
Received: March 2, 2011

Dear Ms. Haselton:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related

adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Herbert P. Lerner, M.D., Director (Acting)
Division of Reproductive, Gastro-Renal
and Urological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K110038

Device Name: TRUCLEAR Morcellation System

Indications For Use:

The TRUCLEAR™ Morcellator System is intended for use in gynecological procedures by trained professional gynecologists to resect and remove endometrial tissue for the following indications, submucous myomas and endometrial polyps.


Prescription Use x
(Per 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


(Division Sign-Off)

Division of Reproductive, Gastro-Renal, and
Urological Devices

510(k) Number K110038